Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development	$ 63,029	$ 52,705
General and administrative	11,904	9,699
Total operating expenses	74,933	62,404
Loss from operations	(74,933)	(62,404)
Other income:
Interest income	2,952	4,057
Other expense, net	(5)	(1)
Total other income, net	2,947	4,056
Net loss	$ (71,986)	$ (58,348)
Net loss per share attributable to common stockholders, basic	$ (0.52)	$ (0.49)
Net loss per share attributable to common stockholders, diluted	$ (0.52)	$ (0.49)
Weighted average common shares outstanding, basic	113,307,940	94,804,659
Weighted average common shares outstanding, diluted	113,307,940	94,804,659
Comprehensive loss:
Net loss	$ (71,986)	$ (58,348)
Other comprehensive income (loss):
Net unrealized gains (losses) on marketable securities	(283)	(285)
Total other comprehensive income (loss)	(283)	(285)
Comprehensive loss	$ (72,269)	$ (58,633)
Series A Non-Voting Convertible Preferred Stock [Member]
Other income:
Net loss per share attributable to common stockholders, basic	$ (131.22)	$ (121.51)
Net loss per share attributable to common stockholders, diluted	$ (131.22)	$ (121.51)
Weighted average common shares outstanding, basic	67,892	74,465
Weighted average common shares outstanding, diluted	67,892	74,465
Series B Non Voting Convertible Preferred Stock [Member]
Other income:
Net loss per share attributable to common stockholders, basic	$ (524.9)	$ (485.97)
Net loss per share attributable to common stockholders, diluted	$ (524.9)	$ (485.97)
Weighted average common shares outstanding, basic	6,868	6,630
Weighted average common shares outstanding, diluted	6,868	6,630